Photo provided by the Chinese Embassy in the Philippines
Bangkok (People’s Daily) - The Philippine Food and Drug Administration (FDA) has approved Chinese drug Lian Hua Qing Wen produced by one of China’s renowned traditional Chinese medicine (TCM) manufacturers, Shijiazhuang Yiling Pharmaceutical Co Ltd, making the drug formally registered as TCM in the Philippines. The Chinese Embassy in the Philippines said that this marks important progress in the entry of TCM products into the Philippine market.
The Lianhua Qingwen capsule is an approved COVID-19 treatment for mild and moderate cases in China. So far, Lianhua Qingwen has been approved in Hong Kong and Macao SAR of China, Brazil, Indonesia, Canada, Mozambique, Romania, Thailand, Ecuador, Singapore and Laos.
“It is our sincere hope that its entrance into the Philippine market will contribute to the fight against the spread of COVID-19 in this country and help the patients with mild and moderate symptoms recover,” said the spokesperson of the Embassy of China.
The spokesperson advised consumers to purchase and consume authentic TCM produced from qualified pharmaceutical manufacturers, and hopes that TCM will play a bigger role in supporting the efforts of the Philippine government and its people to fight against COVID-19 until the final victory.